By Robert Michel, from the Volume XXI NO. 2 – February 3, 2014 issue
Last month, it was announced that Solstas Lab Partners of Greensboro, North Carolina, had agreed to be sold to Quest Diagnostics Incorporated. The sales price is $570 million and financial analysts on Wall Street estimate that the annual revenue at Solstas Lab Partners is about $350 million. This would indicate that Quest Diagnostics paid a
By Robert Michel, from the Volume XIX No. 18 - December 31, 2012 issue
CEO SUMMARY: It’s been a year with more lows than highs, when viewed through the lens of THE DARK REPORT’S “Top Ten Lab Stories of 2012.” The end of the TC grandfather clause, new policies for prostate biopsy billing, and a dramatic 52% cut to 88305- TC fees were widely reported. But there was equally
By Joseph Burns, from the Volume XIX No. 9 - June 25, 2012 issue
CEO SUMMARY: Business intelligence is on the verge of becoming the next “big thing” in clinical laboratory management. Lab teams are using real-time data dashboards to quickly identify problems and take proactive steps to raise service levels to clients. South Bend Medical Foundation says these software systems and related tools are helping it raise the
By Robert Michel, from the Volume XIX No. 3 - February 20, 2012 issue
In its effort to change how code stacking is used to bill for certain genetic and molecular tests, Palmetto GBA announced changes to its Molecular Diagnostic Services Program (MolDx). Earlier this month, the Medicare carrier announced that the effective date for claim submissions under MolDx would move from March 1, 2012, to May 1, 2012.
By Robert Michel, from the Volume XVII No. 4 - March 8, 2010 issue
CEO SUMMARY: In Dallas, Pathologists Bio-Medical Laboratories is part of a new laboratory partnership that includes Baylor Health Care System, Texas Oncology, and US Oncology. The four partners ponied up a total of $40 million in cash and debt to build a state-of-the art laboratory in a 172,000 square foot building. To be called “MedFusion,”
By Robert Michel, from the Volume XVI No. 15 - November 02, 2009 issue
CEO SUMMARY: In concept, it is a simple deal. Catholic Health Initiatives (CHI), the nation’s second largest Catholic health system, is taking a 25% equity position in Pathology Associates Medical Laboratories (PAML). However, the consequences may be significant. PAML now has an open door to develop laboratory joint ventures with the 78 hospitals operated by
By Robert Michel, from the Volume XV No. 17 - December 22, 2008 issue
Last Thursday, Sunquest Information Systems, Inc. of Tucson, Arizona, announced that it would purchase the “Outreach Advantage Solution” software system developed by Pathology Associates Medical Laborator ies of Spokane, Washington. PAML has spent most of this decade developing a comprehensive, integrated software system designed specifically to give hospital laboratory outreach programs a full service capability
By Robert Michel, from the Volume XIV No. 17 - December 10, 2007 issue
“A well-structured laboratory joint venture helps the hospital partner tap the unrealized value of its laboratory, because the independent lab partner provides capital, along with experience, and expertise to serve and build outreach market share.”
—Thomas Tiffany, Ph.D., CEO, Pathology Associates Medical Laboratories
CEO SUMMARY: Earlier this month, MountainStar Healthcare Network of Salt Lake City, Utah, and
By Robert Michel, from the Volume IX No. 11 - August 5, 2002 issue
CEO SUMMARY: Dade Behring is executing an ambitious plan to restructure its finances and become a public company. To reduce its debt burden, Dade’s three owners are giving up their stock. Banks and bondholders will swap a portion of their debt for shares of stock in Dade. Once the financial restructure is completed, Dade Behring
